Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Scientists discover SCUBE3 molecule for potential baldness cure. Mice used in research for hair growth signaling.

A 23-year-old shared their 5-month progress using oral minoxidil (5 mg) and dutasteride (0.5 mg) with no side effects, reporting thicker hair and some hairline improvement. They used Avodart for dutasteride and Labinco for minoxidil, and others in the conversation discussed their experiences and interest in similar treatments.

The user experienced hair loss due to defective dutasteride and is now using a regimen including dutasteride, oral and topical minoxidil, RU58841, tretinoin, and microneedling to recover hair density. They are optimistic about regaining their hair despite recent setbacks.

Avoid clinics that push for more grafts than necessary, as it can lead to unnecessary costs and damage to the donor area. Trust reputable clinics and be cautious of those using celebrity endorsements or offering suspiciously low prices.

People are humorously discussing unconventional and extreme methods of using hair loss treatments like finasteride and minoxidil, including vaping, snorting, and injecting. The conversation is filled with jokes and sarcasm about these methods.

The user plans to start hair loss treatment with minoxidil, finasteride, and microneedling, considering oral minoxidil to avoid affecting their cat. They are concerned about potential shedding and the impact of vaping on hair loss.

The user is using finasteride, HGH, GHK-CU, BPC-157, KPV, biotin/collagen/keratin vitamins, ketoconazole shampoo, and low-dose naltrexone to address hair loss, avoiding minoxidil due to past shedding experiences. Adenosine is discussed as a potential alternative to minoxidil, though it is noted to be expensive and hard to find.

Using a combination of micro-needling and exosome injections as a potential treatment for male pattern baldness, which could result in 50% or more regrowth.

A user experimenting with an extreme hair loss treatment stack of Dutasteride, RU58841, 15 mg oral minoxidil, and microneedling, which sparked a debate among other users about the safety of this approach.

Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

Breezula passed a clinical trial in August and there are questions about its availability in 2021 and potential delays due to Covid. No specific treatments were discussed.

The conversation discusses an extensive hair loss treatment regimen including dutasteride, GT20029, RU58841, pyrilutamide, minoxidil, microneedling, ketoconazole shampoo, and experimental compounds. The user humorously describes their approach as a comprehensive strategy to combat hair loss while maintaining hair growth.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

Dutasteride tablets are less effective than softgel capsules because they require a fat-based environment for proper absorption. Softgel capsules, like Avodart, are designed to maximize bioavailability, while powdered tablets may result in significantly lower DHT suppression.

The conversation discusses Dr. Blake Bloxham's experiment with Verteporfin for hair loss, with one person suggesting more doctors should try it as it seems beneficial. Another comment notes that results at 4-5 months were not very impressive.

A 29-year-old male with androgenic alopecia was treated with oral Dutasteride, oral Minoxidil, and injectable Dutasteride, showing progress in 9 months. Some users believe Dutasteride mesotherapy is unnecessary and question its effectiveness compared to topical applications.

Users discussed hair loss treatments, specifically 0.1% latanoprost with melatonin, caffeine, and biotin. Other treatments mentioned include minoxidil, finasteride, RU58841, and microneedling.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

The user is experiencing diffuse hair thinning despite using dutasteride and minoxidil for over five years and is considering adding oral minoxidil, microneedling, and nizoral to their regimen. They are concerned about the effectiveness and side effects of these treatments, especially with an upcoming event.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

Finasteride is effective for DHT/AR-driven hair loss but not for chromosome 20-driven cases, where treatments like minoxidil, prostaglandin analogs, and low-level laser therapy may be more beneficial. Genetic testing can help determine the underlying cause of hair loss to tailor treatment effectively.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.